ATRA Atara Biotherapeutics Inc
Price (delayed)
$6.01
Market cap
$35.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.41
Enterprise value
$78.57M
Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers
Highlights
The EPS has soared by 82% YoY and by 56% from the previous quarter
The net income has soared by 69% YoY and by 36% from the previous quarter
Atara Biotherapeutics's quick ratio has decreased by 45% YoY and by 25% QoQ
The equity has declined by 7% since the previous quarter
Key stats
What are the main financial stats of ATRA
Market
Valuations
Earnings
Shares outstanding
5.86M
Market cap
$35.21M
Enterprise value
$78.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.61
Revenue
$128.94M
Gross profit
$107.93M
Operating income
-$83.44M
Net income
-$85.4M
EBIT
-$80.8M
EBITDA
-$63.62M
Free cash flow
-$68.96M
Per share
Balance sheet
Liquidity
EPS
-$11.41
EPS diluted
-$11.41
Free cash flow per share
-$9.21
Book value per share
-$16.89
Revenue per share
$17.22
TBVPS
$14.57
Total assets
$109.1M
Total liabilities
$206.38M
Debt
$68.54M
Equity
-$97.28M
Working capital
-$69.68M
Debt to equity
-0.7
Current ratio
0.48
Quick ratio
0.33
Net debt/EBITDA
-0.68
Margins
Efficiency
Dividend
EBITDA margin
-49.3%
Gross margin
83.7%
Net margin
-66.2%
Operating margin
-64.7%
Return on assets
-63.9%
Return on equity
N/A
Return on invested capital
-457.3%
Return on capital employed
N/A
Return on sales
-62.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATRA stock price
How has the Atara Biotherapeutics stock price performed over time
Intraday
1.18%
1 week
-13.15%
1 month
-13.02%
1 year
-66.85%
YTD
-54.85%
QTD
1.18%
Financial performance
How have Atara Biotherapeutics's revenue and profit performed over time
Revenue
$128.94M
Gross profit
$107.93M
Operating income
-$83.44M
Net income
-$85.4M
Gross margin
83.7%
Net margin
-66.2%
The net margin has soared by 98% YoY and by 50% from the previous quarter
ATRA's operating margin has surged by 98% year-on-year and by 50% since the previous quarter
The operating income has soared by 70% YoY and by 36% from the previous quarter
The net income has soared by 69% YoY and by 36% from the previous quarter
Growth
What is Atara Biotherapeutics's growth rate over time
Valuation
What is Atara Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.61
The EPS has soared by 82% YoY and by 56% from the previous quarter
The equity has declined by 7% since the previous quarter
ATRA's P/S is 99% below its 5-year quarterly average of 56.4 and 74% below its last 4 quarters average of 1.3
Atara Biotherapeutics's revenue has increased by 28% QoQ
Efficiency
How efficient is Atara Biotherapeutics business performance
Atara Biotherapeutics's return on invested capital has shrunk by 189% YoY and by 16% QoQ
The ROS has soared by 98% YoY and by 51% from the previous quarter
The company's return on assets rose by 48% YoY and by 29% QoQ
Dividends
What is ATRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATRA.
Financial health
How did Atara Biotherapeutics financials performed over time
The total assets is 47% less than the total liabilities
Atara Biotherapeutics's quick ratio has decreased by 45% YoY and by 25% QoQ
The total assets has contracted by 34% YoY and by 24% from the previous quarter
The debt is 170% more than the equity
The debt has decreased by 15% YoY and by 6% from the previous quarter
ATRA's debt to equity is up by 14% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.